Collaborative Innovations in Childhood Cancer Therapies.

Iris Valtingojer, Sasha Lièvre, Philippe Bordes, Krupa Paranjpe, Winifred Thompson, Sachin Shah, Valeria Fantin, Wendy Jacquemet-Ross, Peter C Adamson

Abstract readReview

PubMed Publisher

In one paragraph

Review in Handbook of experimental pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Iris ValtingojerDepartment of Oncology, R&D, Sanofi, Vitry-sur-Seine, France. Iris.Valtingojer@sanofi.com.

Sasha LièvreDepartment of Oncology, R&D, Sanofi, Vitry-sur-Seine, France.

Philippe BordesDepartment of Alliance Management and Public Private Partnerships, Sanofi, Gentilly, France.

Krupa ParanjpeDepartment of Oncology Medical Affairs, Sanofi, Cambridge, MA, USA.

Winifred ThompsonDepartment of Oncology Medical Affairs, Sanofi, Cambridge, MA, USA.

Sachin ShahDepartment of Oncology Medical Affairs, Sanofi, Cambridge, MA, USA.

Valeria FantinDepartment of Oncology, R&D, Sanofi, Cambridge, MA, USA.

Wendy Jacquemet-RossPartnerships Team, LifeArc, London, UK.

Peter C AdamsonDepartment of Oncology, R&D, Sanofi, Cambridge, MA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The outcome for children with cancer has improved significantly over the past 60 years, with more than 80% of patients today becoming 5-year survivors. Despite this progress, cancer remains the leading cause of death from disease in children in the United States and Europe, with significant short- and long-term toxicity of treatment continuing to impact most children. While the past 15 years have witnessed dramatic scientific innovation for certain cancers in adult patients, pediatric cancer treatment innovation lags increasingly behind. To help bridge the adult-pediatric therapeutic development gap, collaborative efforts are essential among stakeholders within and outside the pediatric oncology community. Prioritizing collaboration in areas such as cancer characterization, target identification and validation, drug discovery, and approaches to currently "undruggable" targets is imperative to improving the outcomes for children with cancer.

Indexed as

NeoplasmsAntineoplastic AgentsChildDrug DiscoveryHumansAntineoplastic AgentsChildhood cancerCollaborationsNovel therapiesPartnershipsResearch and Development

Identifiers

PMID39177748

DOI10.1056/NEJMoa1508054

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.